Marcelo Bendix, MD
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1053365551
Payments from drug & device makers
Across 946 payments — averaging $34.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$22K
- Novo Nordisk$4K
- Mannkind Corporation$1K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$742
- Dexcom, Inc.$485
- plus $4K from 27 others
What the payments were for
- Consulting fees$1,4855%
- Speaking & faculty fees$16,95052%
- Food & beverage$13,98243%
- Education$150%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 586 | $21,646 |
| Novo Nordisk | 98 | $3,668 |
| Mannkind Corporation | 51 | $1,260 |
| Sanofi-aventis U.S. LLC | 22 | $1,121 |
| AstraZeneca | 17 | $742 |
| Dexcom, Inc. | 5 | $485 |
| Lilly USA, LLC | 29 | $482 |
| Zealand Pharma US, Inc. | 19 | $415 |
| Medtronic | 14 | $260 |
| Corcept Therapeutics | 11 | $242 |
| Bayer | 6 | $232 |
| Tandem Diabetes Care, Inc. | 9 | $228 |
| Lifescan, Inc. | 8 | $215 |
| Boehringer Ingelheim | 10 | $202 |
| Amarin Pharma, Inc. | 9 | $198 |
| AbbVie | 7 | $144 |
| Cequr Corporation | 2 | $126 |
| Abbott | 6 | $123 |
| Amneal Pharmaceuticals LLC | 7 | $122 |
| Xeris Pharmaceuticals, Inc. | 5 | $114 |
| Radius Health, Inc. | 4 | $95 |
| Amgen | 4 | $69 |
| IBSA Pharma Inc. | 3 | $54 |
| Kyowa Kirin, Inc. | 3 | $50 |
| Halozyme Inc | 2 | $47 |
| Embecta Corp. | 2 | $38 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Novartis | 1 | $32 |
| BD | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$17,141
- Victoza$1,485
- Ozempic$595
- AFREZZA$588
- SOLIQUA 100/33$550
- FARXIGA$374
- RYBELSUS$363
- DEXCOM G6 TRANSMITTER$341
- DEXCOM G7 GSS (161)$125
- TOUJEO$123
- Kerendia$121
How this compares
$32,551 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,066 | $1,231,935 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 669 | $731,188 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 405 | $615,967 |
| MounjaroTirzepatide | 423 | $537,391 |
| JardianceEmpagliflozin | 331 | $343,852 |
| TrulicityDulaglutide | 213 | $243,467 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 123 | $182,348 |
| JanumetSitagliptin Phos/Metformin Hcl | 229 | $171,650 |
| RybelsusSemaglutide | 111 | $160,253 |
| FarxigaDapagliflozin Propanediol | 167 | $158,468 |
| TradjentaLinagliptin | 165 | $117,947 |
| AfrezzaInsulin Regular, Human | 41 | $106,723 |
| JanuviaSitagliptin Phosphate | 79 | $81,109 |
| NovologInsulin Aspart | 291 | $67,761 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $61,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $3,668 | $1,476,5461,484 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $482 | $849,292795 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,121 | $731,188669 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto, Glyxambi | $202 | $540,004581 claims |
| AstraZenecaFarxiga | $742 | $158,468167 claims |
| Mannkind CorporationAfrezza | $1,260 | $106,72341 claims |
| AbbVieSynthroid | $144 | $59,991513 claims |
| AmgenProlia | $69 | $57,11233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Miami
- Rodolfo GalindoMiami$2.5M
- Eugenio Angueira-SerranoMiami$2.2M
- Jay SkylerMiami$2.2M
- Camillo RicordiMiami$1.4M
- Gianluca IacobellisMiami$346K
- Carlos BarreraMiami$157K
- Marilu JuradoMiami$146K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.